Affiliation:
1. INRA Université de Bordeaux 2, UMR Génomique Développement Pouvoir Pathogène, 71 avenue Edouard Bourlaux, 33883 Villenave D'Ornon, France
2. Université de Rennes I, UMR CNRS 6026 Interactions Cellulaires et Moléculaires, Campus de Beaulieu, 35042 Rennes, France
Abstract
ABSTRACT
We showed in a previous study that associations of antimicrobial peptides (AMPs), which are key components of the innate immune systems of all living species, with the fluoroquinolone enrofloxacin can successfully cure HeLa cell cultures of
Mycoplasma fermentans
and
M. hyorhinis
contamination. In the present work, the in vitro susceptibility of
M. pulmonis
, a murine pathogen, to enrofloxacin and four AMPs (alamethicin, globomycin, gramicidin S, and surfactin) was investigated, with special reference to synergistic associations and the effect of the mycoplasma cell concentration. Enrofloxacin and globomycin displayed the lowest MICs (0.4 μM), followed by gramicidin S (3.12 μM), alamethicin (6.25 μM), and surfactin (25 μM). When the mycoplasma cell concentration was varied from 10
4
to 10
8
CFU/ml, the MICs of enrofloxacin and globomycin increased while those of the three other molecules remained essentially constant. The minimal bactericidal concentration of enrofloxacin (0.8 μM) was also lower than those of the peptides (6.25 to 100 μM), but the latter killed the mycoplasma cells much faster than enrofloxacin (2 h versus 1 day). The use of the AMPs in association with enrofloxacin revealed synergistic effects with alamethicin and surfactin. Interestingly, the mycoplasma-killing activities of the two combinations enrofloxacin (MIC/2) plus alamethicin (MIC/4) and enrofloxacin (MIC/2) plus surfactin (MIC/16) were about 2 orders of magnitude higher than those of the three molecules used separately. These results support the interest devoted to AMPs as a novel class of antimicrobial agents and pinpoint their ability to potentiate the activities of conventional antibiotics, such as fluoroquinolones.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference27 articles.
1. Andres, E., and J. L. Dimarcq. 2004. Cationic antimicrobial peptides: update of clinical development. J. Intern. Med.255:519-520.
2. Bébéar, C. M., and I. Kempf. 2005. Antimicrobial therapy and antimicrobial resistance, p. 535-568. In A. Blanchard and G. Browning (ed.), Mycoplasmas. Molecular biology, pathogenicity, and strategies for control. Horizon Bioscience, Norfolk, United Kingdom.
3. Béven, L., M. Le Henaff, C. Fontenelle, and H. Wróblewski. 1996. Inhibition of spiralin processing by the lipopeptide antibiotic globomycin. Curr. Microbiol.33:317-322.
4. Béven, L., and H. Wróblewski. 1997. Effect of natural amphipathic peptides on viability, membrane potential, cell shape and motility of mollicutes. Res. Microbiol.148:163-175.
5. Blanchard, A., and C. M. Bébéar. 2002. Mycoplasmas of humans, p. 45-71. In S. A. Razin and R. Herrmann (ed.), Molecular biology and pathogenicity of mycoplasmas. Kluwer Academic Plenum, New York, NY.
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献